The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer, preferably colorectal cancer (CRC), in a subject. The method is based on the determination of the level of a panel of least one, preferably 3, 4 and most preferably at least 5, protein biomarker selected from the group consisting of the protein biomarkers Amphiregulin (AREG), Carcinoembryonic antigen (CEA), Insulin like growth factor binding protein 2 (IGFBP2), Keratin, type I cytoskeletal 19 (KRT19), Mannan binding lectin serine protease 1 (MASP1), Osteopontin (OPN), Serum paraoxonase lactonase 3 (PON3) and Transferrin receptor protein 1 (TR), in the biological sample obtained from the subject. The new biomarker panel of the invention allows diagnosing and even stratifying various cancer diseases. Furthermore, provided are diagnostic kits for performing the non-invasive methods of the invention. Since the biomarker panel of the invention provides a statistically robust method independent of the protein detection technology used, and considering that the biomarker panel of the invention is detected in plasma samples of the subjects, the invention provides an early detection screening examination that may be applied to a larger population.

According to one embodiment, a sensor for detecting a target substance in gas a sample includes a target substance uptake unit that brings an acetylcholine aqueous solution into contact with a gas sample to dissolve a target substance in the gas sample into the acetylcholine aqueous solution, a reaction unit that holds acetylcholinesterase and brings the solution delivered from the target substance uptake unit into contact with the acetylcholinesterase, and a detection unit that measures a change in an amount of acetylcholine decomposition product produced in the solution delivered from the reaction unit.

Disclosed are compositions and methods for detecting leukocyte esterase (LE) activity in a sample. The method can include contacting the sample with an assay sample comprising methyl pyruvate and alcohol oxidase to form a test sample, measuring H.sub.2O.sub.2 produced from contacting the sample and the assay sample in the test sample.

The RGO (Reduced Graphene Oxide)-based bio sensor according to the present invention comprises: a source electrode and a drain electrode formed on a substrate; an RGO channel formed between the source electrode and the drain electrode; a PDMS (polydimethylsiloxane) chip supplying a reaction solution to the RGO channel; a passivation layer for sealing in order to prevent the reaction solution supplied through the PDMS chip from touching the source electrode and the drain electrode; and a gate electrode electrically connected to the reaction solution contacted to the RGO by being supplied through the PDMS chip.

At this time, the passivation layer is formed with a SU-8 photoresistor, and the gate electrode is directly contacted to the reaction solution to thereby realize a liquid phase driving. The passivation layer is formed with SU-8 to allow supply of reaction solution through PDMS chip to be conveniently and stably realized. The operation is made possible at a gate voltage of −1.0V˜1.0V due to liquid driving of gate electrode, thereby enabling to realize FET type bio sensor having a high sensitivity.

An immunoassay test slide for use in a dry chemistry analytical instrument includes a slide housing or case formed from two matable sections—a slide cover piece and a slide bottom piece. The slide housing defines an interior cavity in which is situated a sheet-like porous carrier matrix. The slide cover piece has an opening formed through the thickness thereof to expose a central portion of the fluid flow matrix so that a precise volume of fluid sample of blood, serum or the like, preferably pre-mixed with a conjugate reagent, and precise volumes of a wash reagent and a substrate (detector reagent), may be deposited on the matrix through the cover opening by a metering device of the analytical instrument. The bottom piece of the immunoassay test slide is transparent, and the slide is moved by a transport mechanism of the analytical instrument over a reflectometer or a fluorometer for performing reflectance or fluorescence measurements.

The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

Methods and kits for diagnosis and staging of shock, and especially non-septic shock are presented in which protease activities and/or volatile compounds are measured from a biological sample to so identify and/or stage shock.

A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.

A practical and effective method for low abundance host cell protein (HCP) identification and quantification, which facilitates the downstream purification process in eliminating potentially problematic HCPs. In particular, the method comprises performing a native digestion followed by characterization using Multiple Reaction Monitoring approach.

Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MM) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.